[1]张莉,陈利红,李霞,等.IL-17A单克隆抗体治疗诱导期对寻常性银屑病患者血清细胞因子的影响[J].中国皮肤性病学杂志,2020,(11):1249-1254.[doi:10.13735/j.cjdv.1001-7089.202002067]
 ZHANG Li,CHEN Lihong,LI Xia,et al.Early-effect of Anti-IL-17A for Serum Inflammation Related Cytokines Levels in Patients with Psoriasis Vulgaris[J].The Chinese Journal of Dermatovenereology,2020,(11):1249-1254.[doi:10.13735/j.cjdv.1001-7089.202002067]
点击复制

IL-17A单克隆抗体治疗诱导期对寻常性银屑病患者血清细胞因子的影响()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2020年11期
页码:
1249-1254
栏目:
论著
出版日期:
2020-11-01

文章信息/Info

Title:
Early-effect of Anti-IL-17A for Serum Inflammation Related Cytokines Levels in Patients with Psoriasis Vulgaris
文章编号:
1001-7089(2020)11-1249-06
作者:
张莉陈利红李霞薛峰乐云辰胡梦妍徐倩楠郑捷
上海交通大学医学院附属瑞金医院皮肤科,上海 200025
Author(s):
ZHANG LiCHEN LihongLI XiaXUE FengLE YunchenHU MengyanXU QiannanZHENG Jie
Department of Dermatology Ruijin Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China
关键词:
银屑病 司库奇尤单抗 细胞因子 PASI
Keywords:
Psoriasis Secukinumab Cytokine PASI score
分类号:
R 758.63
DOI:
10.13735/j.cjdv.1001-7089.202002067
文献标志码:
A
摘要:
目的 观察抗IL-17A单克隆抗体(司库奇尤单抗)治疗前后寻常性银屑病患者血清细胞因子的变化,探讨细胞因子的检测在其疗效评价中的意义。方法 收集接受司库奇尤单抗治疗的21例寻常性银屑病患者临床资料,采集外周血,通过流式多因子微珠阵列(cytometric bead array,CBA)检测患者血清中IL-1β、IL-2、IL-5、IL-6、IL-8、IL-10、IL-12p70、IL-17A、IFN-γ浓度。结果 寻常性银屑病患者血清中细胞因子IL-8(P<0.01)、IL-17A(P=0.03)与患者PASI评分正相关,司库奇尤单抗治疗后5周患者血清细胞因子IL-2(P<0.05)、IL-17A(P<0.05)水平升高,IL-6水平降低(P<0.05),但IL-1β、IL-5、IL-8、IL-10、IL-12p70、IFN-γ水平的差异无统计学意义(P>0.05)。与治疗前相比,治疗12周后患者血清细胞因子IL-1β(P<0.05)、IL-12p70(P<0.05)水平升高,IL-17A(P<0.05)水平持续上升。同时,原本降低的IL-6水平上升(P<0.05)。司库奇尤单抗治疗后患者皮损改善程度与血清中细胞因子ΔIL-6(P<0.05)、ΔIL-5(P=0.03)呈正相关(P=0.01)。结论 在司库奇尤单抗治疗寻常性银屑病早期监测中,血清细胞因子IL-5、IL-6的变化与PASI评分的改善具有显著相关性,可能作为寻常性银屑病患者评估疗效的客观生物标记。
Abstract:
Objective To investigate serum cytokines in psoriasis vulgaris patients before and after IL-17A inhibition by secukinumab.We want to explore whether the detection of cytokines can be used to evaluate the efficacy and sensitivity.MethodsTwenty-one patients with psoriasis vulgaris treated with secukinumab were selected.Serum samples were obtained from these patients,and cytometric bead array(CBA)was performed to detect the levels of interleukin(IL)-1β、IL-5、IL-6、IL-8、IL-10、IL-12p70、IL-17A、IFN-γ.Results Serum cytokines IL-8(P<0.05)and IL-17A(P<0.05)were positively correlated with PASI score.After 5-weeks treatment,these patients showed significantly increased serum levels of IL-2(P<0.05),IL-17A(P<0.05),while IL-6(P<0.05)decreased.However,there was no significant difference in the serum level of IL-1β、IL-5、IL-8、IL-10、IL-12p70、IFN-γ after treatment.After 12-weeks treatment,these patients showed significantly increased serum levels of IL-1β(P<0.05),IL-12p70(P<0.05)and IL-17A(P<0.05),IL-6 which was down-regulated after 5weeks treatment,also increased at 12 weeks(P<0.05).The improvement of PASI score was positively correlated with ΔIL-5(P<0.05)and ΔIL-6(P<0.05)in serum.Conclusion The change of serum IL-5、IL-6 was positively correlated with PASI score,and these cytokines may be used as a biomarker clinically to evaluate the treatment efficacy.

参考文献/References:

[1] 乔菊,高祎濛,李峰,等.银屑病患者外周血TNF-α、IL-17A、IL-23、IL-36γ表达水平及临床意义[J].中国皮肤性病学杂志,2019,33(3):280-284.
[2] Blauvelt A,Chiricozzi A.The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis[J].Clin Rev Allergy Immunol,2018,55(3):379-390.
[3] Ogawa E,Sato Y,Minagawa A,et al.Pathogenesis of psoriasis and development of treatment[J].J Dermatol,2018,45(3):264-272.
[4] Okubo K,Kamiya M,Urano Y,et al.Lactoferrin suppresses neutrophil extracellular traps release in inflammation[J].Ebio Medicine,2016,10:204-215.
[5] Reich K,Papp KA,Matheson RT,et al.Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis[J].Exp Dermatol,2015,24(7):529-535.
[6] 中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018完整版)[J].中华皮肤科杂志,2019,52(10):667-710.
[7] Solberg SM,Sandvik LF,Eidsheim M,et al.Serum cytokine measurements and biological therapy of psoriasis-prospects for personalized treatment?[J].Scand J Immunol,2018,88(6):e12725.
[8] Krueger JG,Wharton KA Jr,Schlitt T,et al.IL-17A inhibition by secukinumab induces early clinical,histopathologic,and molecular resolution of psoriasis[J].J Allergy Clin Immunol,2019,144(3):750-763.
[9] Reich K,Armstrong AW,Foley P,et al.Efficacy and safety of guselkumab,an anti-interleukin-23 monoclonal antibody,compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment:Results from the phase III,double-blind,placebo- and active comparator-controlled VOYAGE 2 trial[J].J Am Acad Dermatol,2017,76(3):418-431.
[10] Reich K,Armstrong AW,Langley RG,et al.Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis(ECLIPSE):results from a phase 3,randomised controlled trial[J].Lancet,2019,394(10201):831-839.
[11] Gordon KB,Strober B,Lebwohl M,et al.Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis(UltIMMa-1 and UltIMMa-2):results from two double-blind,randomised,placebo-controlled and ustekinumab-controlled phase 3 trials[J].Lancet,2018,392(10148):650-661.
[12] Walters HM,Pan N,Lehman TJ,et al.The impact of disease activity and tumour necrosis factor-alpha inhibitor therapy on cytokine levels in juvenile idiopathic arthritis[J].Clin Exp Immunol,2016,184(3):308-317.
[13] Kolbinger F,Loesche C,Valentin MA,et al.beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis[J].J Allergy Clin Immunol,2017,139(3):923-932.
[14] De Rie MA,Zonneveld IM,Witkamp L,et al.Soluble interleukin-2 receptor(sIL-2R)is a marker of disease activity in psoriasis:a comparison of sIL-2R,sCD27,sCD4,sCD8 and sICAM-1[J].Acta Derm Venereol,1996,76(5):357-360.
[15] Tsai YC,Tsai TF.Anti-interleukin and interleukin therapies for psoriasis:current evidence and clinical usefulness[J].Ther Adv Musculoskelet Dis,2017,9(11):277-294.
[16] Blauvelt A.IL-6 differs from TNF-alpha:unpredicted clinical effects caused by IL-6 blockade in psoriasis[J].J Invest Dermatol,2017,137(3):541-542.
[17] Hunter CA,Jones SA.IL-6 as a keystone cytokine in health and disease[J].Nat Immunol,2015,16(5):448-457.
[18] Fritz Y,Klenotic PA,Swindell WR,et al.Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO Mice[J].J Invest Dermatol,2017,137(3):696-705.
[19] 杨皎,董昕煜,来宝长,等.LL-37对银屑病患者T细胞分泌白介素-8的作用[J].中国皮肤性病学杂志,2015,29(9):904-906.
[20] 车敦发,曹扬,管海宏,等.抗白细胞介素-8单克隆抗体乳膏治疗寻常型银屑病的临床研究[J].医学研究生学报,2006,19(6):548-550.
[21] Teng MW,Bowman EP,McElwee JJ,et al.IL-12 and IL-23 cytokines:from discovery to targeted therapies for immune-mediated inflammatory diseases[J].Nat Med,2015,21(7):719-729.
[22] Khandpur S,Gupta V,Das D,et al.Is there a correlation of serum and tissue T helper-1 and -2 cytokine profiles with psoriasis activity and severity? A cross-sectional study[J].Indian J Dermatol Venereol Leprol,2018,84(4):414-418.
[23] Imafuku S,Honma M,Okubo Y,et al.Efficacy and safety of secukinumab in patients with generalized pustular psoriasis:A 52-week analysis from phase III open-label multicenter Japanese study[J].J Dermatol,2016,43(9):1011-1017.
[24] Saeki H,Nakagawa H,Nakajo K,et al.Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis,erythrodermic psoriasis and generalized pustular psoriasis:Results from a 52-week,open-label,phase 3 study(UNCOVER-J)[J].J Dermatol,2017,44(4):355-362.
[25] Munera-Campos M,Ballesca F,Richarz N,et al.Paradoxical eczematous reaction to ixekizumab[J].J Eur Acad Dermatol Venereol,2019,33(1):e40-e42.
[26] Burlando M,Cozzani E,Russo R,et al.Atopic-like dermatitis after secukinumab injection:A case report[J].Dermatol Ther,2019,32(1):e12751.
[27] Campanati A,Orciani M,Lazzarini R,et al.TNF-alpha inhibitors reduce the pathological Th1-Th17/Th2 imbalance in cutaneous mesenchymal stem cells of psoriasis patients[J].Exp Dermatol,2017,26(4):319-324.

相似文献/References:

[1]唐娟,张晓艳,宋佩华,等.寻常性银屑病患者皮损及外周血单一核细胞中IL-17A的表达[J].中国皮肤性病学杂志,2012,(08):689.
 TANG Juan,ZHANG Xiao-yan,SONG Pei-hua,et al.Expression of IL-17A in Involved Lesions and Blood Mononuclear Cells of Patients with Psoriaisis[J].The Chinese Journal of Dermatovenereology,2012,(11):689.
[2]戴莎,王秀丽,宋心葵,等.银屑病患者410例合并代谢综合征分析[J].中国皮肤性病学杂志,2012,(08):700.
 DAI Sha,WANG Xiu-li,SONG Xin-kui,et al.Analysis of 410 Cases of Psoriasis Patients with Metabolic Syndrome[J].The Chinese Journal of Dermatovenereology,2012,(11):700.
[3]谢韶琼,汪青良,宋勋,等.凉血润肤汤治疗寻常性银屑病42例疗效观察[J].中国皮肤性病学杂志,2012,(08):743.
 XIE Shao-qiong,WANG Qing-liang,SONG Xun,et al.Clinical Observation of Liangxierunfu Decoction on 42 Cases of Psoriasis Vulgaris[J].The Chinese Journal of Dermatovenereology,2012,(11):743.
[4]广维,朱红,姚树兰,等.伊那西普治疗银屑病的十年回顾[J].中国皮肤性病学杂志,2012,(08):745.
 GUANG Wei,ZHU Hong,YAO Shu-lan,et al.A 10-year Review of Etanercept in the Treatment of Psoriasis[J].The Chinese Journal of Dermatovenereology,2012,(11):745.
[5]史航,刘晓明,林熙然,等.银屑病发病与创伤愈合机制的比较[J].中国皮肤性病学杂志,2012,(08):748.
 SHI Hang,LIU Xiao-ming,LIN Xi-ran.A Comparison on Pathogenesis of Psoriasis and Mechanism of Wound Healing[J].The Chinese Journal of Dermatovenereology,2012,(11):748.
[6]刘晓洁,张峻岭,刘雪,等.头皮银屑病和脂溢性皮炎的皮肤镜特征分析[J].中国皮肤性病学杂志,2015,(01):36.[doi:10.13735/j.cjdv.1001-7089.2015.0036]
 LIU Xiao jie,ZHANG Jun ling,LIU Xue,et al.Analysis of Dermoscopic Criteria for Scalp Psoriasis and Scalp Seborrheic Dermatitis[J].The Chinese Journal of Dermatovenereology,2015,(11):36.[doi:10.13735/j.cjdv.1001-7089.2015.0036]
[7]王彩梅,汤洁,向志,等.甲损害在泛发性脓疱型银屑病中的临床意义[J].中国皮肤性病学杂志,2015,(01):44.[doi:10.13735/j.cjdv.1001-7089.2015.0044]
 WANG Cai mei,TANG Jie,XIANG Zhi,et al.Clinical Significance of Nail Involvement in Generalized Pustular Psoriasis[J].The Chinese Journal of Dermatovenereology,2015,(11):44.[doi:10.13735/j.cjdv.1001-7089.2015.0044]
[8]李珺莹,李红.酪氨酸激酶及其抑制剂与免疫性皮肤病的研究进展[J].中国皮肤性病学杂志,2015,(01):93.[doi:10.13735/j.cjdv.1001-7089.2015.0093]
 LI Jun ying,LI Hong.Tyrosine Kinases and its Inhibitors in Immune Dermatologic Diseases[J].The Chinese Journal of Dermatovenereology,2015,(11):93.[doi:10.13735/j.cjdv.1001-7089.2015.0093]
[9]段茜,程燕,储蕾,等.银屑病与高血压病的相关性分析[J].中国皮肤性病学杂志,2015,(02):143.[doi:10.13735/j.cjdv.1001-7089.201404140]
 DUAN Xi,CHENG Yan,CHU Lei,et al.The Correlation between Psoriasis and Hypertension[J].The Chinese Journal of Dermatovenereology,2015,(11):143.[doi:10.13735/j.cjdv.1001-7089.201404140]
[10]杨颜龙,张禁,易松柏,等.阿维A胶囊联合复方甘草酸苷注射液治疗红皮病型银屑病30例临床观察[J].中国皮肤性病学杂志,2015,(02):217.[doi:10.13735/j.cjdv.1001-7089.201403167]
 YANG Yan long,ZHANG Jin,YI Song bai,et al.Clinical Observation of 30 Acitretin Capsules Combine with Compound Glycyrrhizin Injection in the Treatment of Patients with Erythrodermic Psoriasis[J].The Chinese Journal of Dermatovenereology,2015,(11):217.[doi:10.13735/j.cjdv.1001-7089.201403167]

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金(81830095; 81803134) [通信作者] 郑捷,E-mail:Jie-zheng2001@126.com
更新日期/Last Update: 2020-11-16